ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.73
0.23%
US Tech 100
21,192.80
-0.03%
S&P 500
6,032.75
0.98%
US Dollar vs CAD
1.44099
0.38%
Bitcoin
95,833.05
-3.49%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. RAPT Therapeutics Inc (RAPT) Share Price

RAPT Therapeutics Inc

RAPT Therapeutics Inc (RAPT)

NASDAQ
1.9988
0.2688
( 15.54% )
Updated: 10:12:45
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.9988
Bid
1.99
Ask
2.00
Volume
5,666,067
1.72 Day's Range 2.0599
0.78925 52 Week Range 27.35
Market Cap
69.875M
Previous Close
1.73
Open
1.95
Last Trade
7
@
1.99
Last Trade Time
10:12:41
Financial Volume
US$ 10,717,362
VWAP
1.8915
Average Volume (3m)
3,068,092
Shares Outstanding
34,958,253
Dividend Yield
-
PE Ratio
-0.55
Earnings Per Share (EPS)
-3.34
Revenue
-
Net Profit
-116.8M

About RAPT Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rapt.com
Headquarters
Dover, Delaware, USA
Founded
-
RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPT. The last closing price for RAPT Therapeutics was US$1.73. Over the last year, RAPT Therapeutics shares have traded in a share price range of US$ 0.78925 to US$ 27.35.

RAPT Therapeutics currently has 34,958,253 shares outstanding. The market capitalization of RAPT Therapeutics is US$60.48 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.55.

Ask ADVFN Intelligence (AI)

RAPT Latest News

More News

Form 8-K - Current report

December 23 2024
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

December 23 2024
Edgar (US Regulatory)

Form 8-K - Current report

December 23 2024
Edgar (US Regulatory)

RAPT Therapeutics Announces $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

December 23 2024
GlobeNewswire Inc.

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties...

December 23 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 15 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

November 12 2024
GlobeNewswire Inc.

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

November 11 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.1808144.352078240.8182.320.78925366150921.73262175CS
40.758861.19354838711.242.320.7892583936201.71060396CS
12-0.2312-10.36771300452.233.320.7892530680921.71261474CS
26-1.0812-35.10389610393.083.8250.7892515776181.81539987CS
52-21.8212-91.608732157923.8227.350.7892512936894.83131019CS
156-33.2712-94.332860788235.2740.740.7892566891410.34133835CS
260-28.8412-93.518806744530.8451.20950.7892552116215.07014426CS

RAPT - Frequently Asked Questions (FAQ)

What is the current RAPT Therapeutics share price?
The current share price of RAPT Therapeutics is US$ 1.9988
How many RAPT Therapeutics shares are in issue?
RAPT Therapeutics has 34,958,253 shares in issue
What is the market cap of RAPT Therapeutics?
The market capitalisation of RAPT Therapeutics is USD 60.48M
What is the 1 year trading range for RAPT Therapeutics share price?
RAPT Therapeutics has traded in the range of US$ 0.78925 to US$ 27.35 during the past year
What is the PE ratio of RAPT Therapeutics?
The price to earnings ratio of RAPT Therapeutics is -0.55
What is the reporting currency for RAPT Therapeutics?
RAPT Therapeutics reports financial results in USD
What is the latest annual profit for RAPT Therapeutics?
The latest annual profit of RAPT Therapeutics is USD -116.8M
What is the registered address of RAPT Therapeutics?
The registered address for RAPT Therapeutics is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the RAPT Therapeutics website address?
The website address for RAPT Therapeutics is www.rapt.com
Which industry sector does RAPT Therapeutics operate in?
RAPT Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGIHMillennium Group International Holdings Ltd
US$ 3.97
(159.48%)
64.65M
SPRCSciSparc Ltd
US$ 0.4638
(109.67%)
188.19M
SKKSKK Holdings Limited
US$ 1.44
(92.51%)
18.74M
ZCARZoomcar Holdings Inc
US$ 2.67
(86.71%)
49.32M
PDYNPalladyne AI Corporation
US$ 8.2277
(66.55%)
53.3M
BAOSBaosheng Media Group Holdings Ltd
US$ 4.38
(-38.31%)
1.04M
NEUPNeuphoria Therapeutics Inc
US$ 4.1732
(-37.06%)
354.37k
GTIGraphjet Technology
US$ 0.4096
(-32.85%)
12.06M
DRCTDirect Digital Holdings Inc
US$ 2.57
(-30.73%)
2.92M
SVRESaverOne 2014 Ltd
US$ 1.05
(-30.46%)
801.1k
SPRCSciSparc Ltd
US$ 0.464002
(109.77%)
188.19M
COEPCoeptis Therapeutics Holdings Inc
US$ 0.2124
(49.58%)
169.37M
XTIAXTI Aerospace Inc
US$ 0.0425
(8.42%)
135.22M
RGTIRigetti Computing Inc
US$ 13.63
(20.09%)
100.3M
SMXSMX Security Matters Public Company
US$ 0.2586
(18.62%)
98.07M

RAPT Discussion

View Posts
tw0122 tw0122 2 hours ago
$2.20 + 20%
👍️0
tbonaces80 tbonaces80 5 hours ago
Wainwright ups price to $10. This will be going parabolic 
👍️0
tbonaces80 tbonaces80 15 hours ago
We go hard this week. Too many Capital firms bought in. Load the boat $6-$10 easy
👍️0
tbonaces80 tbonaces80 23 hours ago
This will hit $6 easily. Analysts know. Huge funding.  Foully loaded. 
👍️0
PonkenPlonken PonkenPlonken 1 day ago
@tbonaces80 @Princess17
What do you two think about this?
150 million pp says massively misunderstood story? 140mn historical volume too...
👍️0
tbonaces80 tbonaces80 2 days ago


👍️0
tbonaces80 tbonaces80 2 days ago
Load zone. 
👍️0
Princess17 Princess17 3 days ago
👍🏻 looks good 
👍️0
tbonaces80 tbonaces80 3 days ago
Upgrade. Wells. Yup 
👍️0
PonkenPlonken PonkenPlonken 3 days ago
see chart and compare PP to market cap
must be massively misunderstood

also had a license agreement today
Regards
👍️0
bigbux1 bigbux1 3 days ago
What am I missing? They just did a private placement of 100,000,000 shares of common stock at a purchase price of $0.85 per share and this soars past 1.50?
👍️0
Mister Mr Mister Mr 3 days ago
Keep pumping! Let's go!!!
👍️0
glenn1919 glenn1919 3 days ago
rapt........................https://stockcharts.com/h-sc/ui?s=rapt&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 3 days ago
https://www.globenewswire.com/news-release/2024/12/23/3001133/0/en/RAPT-Therapeutics-Announces-150-Million-Private-Placement.html
wow!
market cap 30 million no discount
👍️0
Invest-in-America Invest-in-America 3 days ago
RAPT:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175569055
👍️0
tw0122 tw0122 3 days ago
RAPT up 15% news and TRAW also up $13.77 + 150% TRAW up big
👍️0
glenn1919 glenn1919 4 weeks ago
RAPT.........................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 months ago
RAPT under $3
👍️0
Monksdream Monksdream 4 months ago
RAPT new 52 week low
👍️0
Monksdream Monksdream 4 months ago
RAPT new 52 low
👍️0
Monksdream Monksdream 5 months ago
RAPT under $4
👍️0
Monksdream Monksdream 8 months ago
RAPT new 52 week
👍️0
Monksdream Monksdream 8 months ago
RAPT under $10
👍️0
tickersym tickersym 10 months ago
Bargin prices!! Lets go!!
👍️0
Stockexpertpro Stockexpertpro 10 months ago
RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
👍️0
StockLogistics StockLogistics 2 years ago
Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
👍️0
StockLogistics StockLogistics 3 years ago
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 years ago
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 years ago
15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.
👍️0
StockLogistics StockLogistics 3 years ago
A ton of insider buying last week
👍️0
StockLogistics StockLogistics 3 years ago
Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
👍️0
Glider549 Glider549 4 years ago
It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.
👍️0
weasel4339 weasel4339 4 years ago
It's way up after hours bud
👍️0
Glider549 Glider549 4 years ago
Can't believe some of you did not take profits near the close.
Greed will kill ya.
👍️0
pennyfinder pennyfinder 4 years ago
Will do
👍️0
weasel4339 weasel4339 4 years ago
I'll keep n eye out. Let me knoe if u hear something about the price
👍️0
pennyfinder pennyfinder 4 years ago
Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
👍️0
weasel4339 weasel4339 4 years ago
This considered dilution?
👍️0
pennyfinder pennyfinder 4 years ago
LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
👍️0
make it happen make it happen 4 years ago
Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
👍️0
pennyfinder pennyfinder 4 years ago
Offering AH or tomorrow pre
👍️0
make it happen make it happen 4 years ago
Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M
👍️0
StockLogistics StockLogistics 4 years ago
This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
👍️0
Roadtojourney Roadtojourney 5 years ago
Not even 6 months old and already offering??
👍️0
crudeoil24 crudeoil24 5 years ago
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
👍️0
crudeoil24 crudeoil24 5 years ago
42.00 > hod.

RAPT
👍️0
crudeoil24 crudeoil24 5 years ago
29.01 x 30.00

RAPT
👍️0
crudeoil24 crudeoil24 5 years ago
Multiple Nasdaq circuit breakers halts today

RAPT
👍️0
crudeoil24 crudeoil24 5 years ago
7.7M shares trading float >

RAPT
👍️0

Your Recent History

NASDAQ
RAPT
RAPT Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads